Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
Novartis
(https://pluvicto.com) 📸 Data Snapshot: May 30, 2026Analyze the raw signals below. How would a machine score this business’s credibility?
Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.
🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) (https://pluvicto.com)
PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan)
Learn more information about PLUVICTO, available before chemotherapy for the treatment of PSMA+ mCRPC. See full Prescribing and Safety Info.
HEADING_REPEATED_BODY What Is PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan)? (https://pluvicto.com/about-pluvicto/how-pluvicto-works/)
What Is PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan)?
Learn how PLUVICTO, the first and only radioligand therapy (RLT) for PSMA+ mCRPC, works as a targeted treatment. See full Prescribing and Safety Info.
HEADING_BODY Treatment Center Locator | PLUVICTO (https://pluvicto.com/treatment-center-locator/)
Treatment Center Locator | PLUVICTO
Access the locator to find the nearest PLUVICTO® (Lutetium Lu 177 vipivotide tetraxetan) treatment center. See full Prescribing and Safety Information.
HEADING_BODY Sign Up | PLUVICTO® (Lutetium Lu 177 vipivotide tetraxetan) (https://pluvicto.com/pluvicto-pulse/)
Sign Up | PLUVICTO® (Lutetium Lu 177 vipivotide tetraxetan)
If you or a loved one are considering PLUVICTO, sign up to receive materials to learn more about treatment for PSMA+ mCRPC. See full Prescribing & Safety Info.
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE (https://pluvicto.com) PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan)
Patient Support Line 1-844-638-7222, Monday-Friday, 8:00 AM – 8:00 PM ET, excluding holidays. [IMG: Man and his daughter standing with PLUVICTO V] PLUVICTO: Every day without progression is a VICTORYWhat Is PLUVICTO?What to expect with treatmentIn the PSMAfore trial, men with PSMA+ mCRPC who received PLUVICTO saw more time without their cancer progressing, with a median of 9.3 months vs 5.6 months with a second hormone therapy. In that study, 49% of men who received PLUVICTO saw their tumors shrink or disappear (vs 14% with a change in hormone therapy). [H5] Available before chemotherapy for PSMA+ mCRPC* *For certain men as determined by their doctor. [H2] How does targeted treatment work for PSMA+ mCRPC?Explore PLUVICTO [H2] Care partners: Find information and materials made for you.Care partner support [H2] Find downloadable materials with additional information.Get helpful materials [H1] Interested in receiving information about PLUVICTO? PLUVICTO® Pulse is a series of emails that helps you talk to your doctor about PLUVICTO.Sign up todayNext: About mCRPC >mCRPC, metastatic castration-resistant prostate cancer; PSMA+, prostate-specific membrane antigen positive.
SUB-PAGE (https://pluvicto.com/about-pluvicto/how-pluvicto-works/) What Is PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan)?
Patient Support Line 1-844-638-7222, Monday-Friday, 8:00 AM – 8:00 PM ET, excluding holidays. [IMG: Man standing inside PLUVICTO V] What IsPLUVICTO? [H2] PLUVICTO is different [H3] It's not chemotherapy. It's targeted treatment called radioligand therapy (RLT). [H4] The FIRST and ONLY RLT for PSMA+ mCRPC RLT is targeted radiation that is injected or infused. PLUVICTO is an RLT that targets a biomarker called PSMA. [H4] Remember it in 3 steps [IMG: PLUVICTO, healthy cells, and PSMA+ cancer cells] PLUVICTO is designed to find and attack PSMA+ cells. PSMA is found on many prostate cancer cells and also some healthy cells. [IMG: Pluvicto attaching to a PSMA+ prostate cancer cell] When PLUVICTO finds PSMA on the surface of a cell, it goes into the cell. [IMG: PLUVICTO entering a cancer cell] Once inside, PLUVICTO releases radiation, damaging or destroying the cell from within. It may also affect some nearby healthy cells. [IMG: Over [25,000] men have already taken PLUVICTO. It could be your next step.] [IMG: Bar chart icon] PLUVICTO has proven results across 2 trialsSee the data [IMG: Thumbnail of Comprehensive Brochure] [H4] Download the PLUVICTO Comprehensive Brochure Get all the information you need about treatment with PLUVICTO.DownloadCopy Link [H1] You’ll receive PLUVICTO at your closest PLUVICTO Treatment Center Treatment Center Locator< Previous: About mCRPCNext: Is PLUVICTO Right For Me? >mCRPC, metastatic castration-resistant prostate cancer; PSMA, prostate-specific membrane antigen; PSMA+, PSMA positive.
SUB-PAGE (https://pluvicto.com/treatment-center-locator/) Treatment Center Locator | PLUVICTO
Patient Support Line 1-844-638-7222, Monday-Friday, 8:00 AM – 8:00 PM ET, excluding holidays. [H1] Find a PLUVICTO Treatment Center [H2] PLUVICTO is available at over 600 treatment centers across the United States. [H3] See below to find the PLUVICTO Treatment Center nearest you. If you need further details, including PLUVICTO availability and supply, please contact the treatment centerTreatment centers may have different patient eligibility criteriaPlease contact the treatment center directly for more information [H3] Please note that PLUVICTO Treatment Centers listed here are only those that have authorized their participation on our website. Please check back regularly, as this list will be periodically updated with newly certified locations.If you are having trouble finding a local treatment site, call the Novartis Patient SupportTM Team at 1-844-638-7222, Monday-Friday, 8:00 AM – 8:00 PM ET, excluding holidaysIf you are a healthcare professional and your site is not listed or you are interested in becoming a treatment center, contact Novartis Patient SupportTM Team at 1-844-638-7222 or your local sales specialist [IMG: Dosing cal icon] You’ll receive PLUVICTO at a treatment center for up to 6 dosesSee what to expect
SUB-PAGE · THIN (https://pluvicto.com/pluvicto-pulse/) Sign Up | PLUVICTO® (Lutetium Lu 177 vipivotide tetraxetan)
Patient Support Line 1-844-638-7222, Monday-Friday, 8:00 AM – 8:00 PM ET, excluding holidays. [IMG: Man playing with his golden retriever with Pluvicto V.] Sign Up ForMore Info [H4] If you or a loved one are considering treatment, PLUVICTO® Pulse can help you learn more It helps in 3 steps:Prepare to talk to your doctorExplore how PLUVICTO could helpKnow what to expect during treatment [IMG: Documents icon] Find additional resources to help prepare you for treatment Find helpful materials [H1] If you already have a prescription for PLUVICTO, call Novartis Patient Support™ at 1-844-638-7222 Learn more< Previous: Care Partner SupportNext: Helpful Materials >mCRPC, metastatic castration-resistant prostate cancer.
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 0 | 0 |
| /about-pluvicto/how-pluvicto-works/ | 0 | 0 |
| /treatment-center-locator/ | 0 | 0 |
| /pluvicto-pulse/ | 1 | 0 |
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage schema
{
"@context": "https://schema.org",
"@type": "Organization",
"@id": "https://us.pluvicto.com/#Organization",
"name": "Novartis",
"url": "https://www.novartis.com/us-en/",
"logo": "https://usim.beprod.us.pluvicto.com/sites/us_pluvicto_com/files/icons/2025-10/logo.svg",
"description": "Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.",
"makesOffer": {
"@type": "Offer",
"@id": "https://us.pluvicto.com/#makesOffer",
"name": "Pluvicto",
"alternateName": "Lutetium Lu 177 vipivotide tetraxetan",
"availability": "https://schema.org/PrescriptionOnly",
"sameAs": "https://us.pluvicto.com/about-pluvicto/how-pluvicto-may-help#offerPluvicto"
}
}
/about-pluvicto/how-pluvicto-works/
{
"@context": "https://schema.org",
"@type": "medicalGuideline",
"@id": "https://us.pluvicto.com/about-pluvicto/how-pluvicto-works#medicalGuideline",
"url": "https://us.pluvicto.com/about-pluvicto/how-pluvicto-works",
"name": "Pluvicto's metastatic Castration-Resistant Prostate Cancer (mCRPC) Medical Guideline",
"legalStatus": "Prescription only, FDA approved",
"description": "Learn about metastatic castration-resistant prostate cancer (mCRPC) and how to find out if you are PSMA+. See full Prescribing and Safety Information.",
"guidelineSubject": {
"@type": "drugClass",
"@id": "https://us.pluvicto.com/about-pluvicto/how-pluvicto-works#drugClass",
"url": "https://us.pluvicto.com/about-pluvicto/how-pluvicto-works",
"description": "PLUVICTO is a prescription treatment used to treat adults with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) already treated with hormon therapy or hormone therapy and chemotherapy",
"drug": {
"@type": "drug",
"@id": "https://us.pluvicto.com/about-pluvicto/how-pluvicto-may-help#drug",
"image": "https://usim.beprod.us.pluvicto.com/sites/us_pluvicto_com/files/icons/2025-10/psma617_pluvicto_r_rgb_us-2.jpg",
"name": "Pluvicto",
"prescribingInfo": "https://www.novartis.com/us-en/sites/novartis_us/files/pluvicto.pdf",
"sameAs": [
"https://en.wikipedia.org/wiki/Lu-PSMA-617",
"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf",
"https://www.novartis.com/us-en/sites/novartis_us/files/pluvicto.pdf",
"https://www.cancer.org/cancer/types/prostate-cancer/treating/radiation-therapy.html",
"https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fb973a8d-7fea-4a7a-963f-2a8e67a46e55"
],
"warning": [
"https://www.novartis.com/us-en/sites/novartis_us/files/pluvicto.pdf",
"low level of blood cell counts",
"tiredness or weakness",
"pale skin",
"shortness of breath",
"bleeding or bruising",
"kidney problems",
"pregnancy complications",
"infertility",
"headache",
"tiredness",
"dry mouth",
"nausea",
"appetite loss",
"join pain",
"constipation",
"back pain"
],
"mechanismOfAction": "https://us.pluvicto.com/about-pluvicto/how-pluvicto-works#mechanismOfAction",
"dosageForm": "Injection",
"availableStrength": {
"@type": "drugStrength",
"activeIngredient": "Lutetium Lu 177 vipivotide tetraxetan",
"sameAs": [
"https://en.wikipedia.org/wiki/Lu-PSMA-617",
"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf",
"https://www.novartis.com/us-en/sites/novartis_us/files/pluvicto.pdf",
"https://medlineplus.gov/druginfo/meds/a622063.html",
"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/lutetium-lu-177-vipivotide-tetraxetan"
],
"strengthUnit": "mCl",
"strengthValue": "200.00"
},
"identifier": {
"@type": "PropertyValue",
"name": "NDC",
"description": "US National Drug Codes",
"sameAs": [
"https://www.novartis.com/us-en/sites/novartis_us/files/pluvicto.pdf",
"https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fb973a8d-7fea-4a7a-963f-2a8e67a46e55",
"https://seer.cancer.gov/oncologytoolbox/canmed/ndconc/69488-0010/",
"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-expands-pluvictos-metastatic-castration-resistant-prostate-cancer-indication"
],
"value": "69488-0010-61"
},
"doseSchedule": {
"@type": "doseSchedule",
"@id": "https://us.pluvicto.com/about-pluvicto/what-to-expect-with-pluvicto-treatment#doseSchedule",
"doseUnit": "mCl",
"doseValue": "200.00",
"frequency": "Consult Physician",
"description": "Refer to the Full Prescribing Information for the recommended dosage. The recommended PLUVICTO dosage is one dose taken intraveneously every six weeks for up to six treatment cycles. "
},
"offers": {
"@type": "Offer",
"@id": "https://us.pluvicto.com/about-pluvicto/how-pluvicto-may-help#offerPluvicto",
"availability": "LimitedAvailability",
"image": "https://usim.beprod.us.pluvicto.com/sites/us_pluvicto_com/files/icons/2025-10/psma617_pluvicto_r_rgb_us-2.jpg",
"priceValidUntil": "2025-12-31",
"url": "https://us.pluvicto.com/about-pluvicto/how-pluvicto-may-help#offerPluvicto",
"price": "50164.84",
"priceCurrency": "USD"
}
}
}
}
Your Diagnosis
Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.
Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)
These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.
Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.
Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.
Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.
Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.
Based on 784 businesses audited.
Novartis has 32.7 points less BS than the average for Medical Devices, Pharma & Biotech.
Medical Devices, Pharma & Biotech BS: Novartis (pluvicto.com)
This site is a benchmark for low-BS medical communication, prioritizing clinical trial transparency and regulatory identifiers over fluff. It provides specific, falsifiable data points that are rare in general business marketing. The forensic markers confirm a site built on substance rather than signal.
Remove the anomalous review_count metadata on the Pulse page if a verified patient review is not intended to be displayed. Add a ‘Last Updated’ timestamp to the 25,000 patient count to ensure the data does not become stale evidence. Ensure the ClinicalTrials.gov identifier is listed in the body text alongside the PSMAfore trial name for even faster verification. Include a direct link to the published peer-reviewed study in the body text rather than just the prescribing PDF.
The website is a textbook example of a high-compliance pharmaceutical brand presence. It strictly adheres to industry standards for mCRPC (metastatic castration-resistant prostate cancer) treatments, focusing on mechanism of action, clinical trial results, and regulatory safety information.
“The score of 8 is driven almost entirely by minor commodity phrasing and a single unverified review count flag. The site excels in Information Density and Identity & Authority, sectors where most sites fail by using generic LocalBusiness schema or fluff-filled H1s. The heavy use of clinical trial metrics and regulatory codes provides a solid floor of substance.”
This training module utilizes a snapshot of public data from Novartis, captured on May 30, 2026, to demonstrate how machine logic evaluates different types of business narratives.
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to compare human intuition against machine-generated evaluations.
Notice to Novartis: This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results provided by 1EuroSEO are intended as professional feedback to help improve any website’s machine-readability and authority signals. The 1EuroSEO BS Detection Tool is a free tool, and anyone can test any company to see how their content is interpreted by AI models.
Any company can use the insights for free and improve its voice by comparing it to industry clichés or competitors. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://pluvicto.com to view the most current version of its content and learn from the source what this company is about and what it offers.